Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention

Shao, Yaodi; Chen, Suzhen; Han, Liu; Liu, Junli

doi:10.1186/s12986-023-00748-x

Nutrition & Metabolism

Table 1 Emerging metabolic pharmacotherapies for NAFLD globally

From: Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention

Drug target	Drugs in trial	Study in population	Outcomes reported	Reference
ACC inhibitor	Firsocostat	NASH	↓ Hepatic lipid content, ↓ fibrosis	[156]
ACC inhibitor	PF-05221304	NASH	↓ Steatosis, ↓ ALT/AST, ↑ Hypertriglyceridema	[157]
FASN inhibitor	TVB 2640	NASH	↓Hepatic lipid content, ↓ ALT, ↓ LDL-C, ↓ Fibrosis	[158]
SCD1 inhibitor	Aramchol	NASH	↓ Hepatic lipid content, ↓ ALT, ↓ Fibrosis	[159, 160]
DGAT inhibitor	PF-06865571	NASH	↓ Hepatic lipid content	[163]
MGAT2 inhibitor	BMS-963,272	NASH (Cynomolgus monkeys)	↓ Inflammation, ↓ Fibrosis	[168]
Hypolipidemic Drugs	Atorvastatin	Hypercholesterolemia with hepatic damage	↓ Hepatic lipid content, ↓ Hepatic enzymes	[171]
Hypolipidemic Drugs	Rosuvastatin	NASH	↓ ALT/AST, ↓ Fibrosis	[218]
FGF21 analogue	Pegbelfermin	NASH	↓ Hepatic lipid content, ↑ Insulin sensitivity	[177]
FGF21 analogue	B1344	NAFLD (Cynomolgus monkeys)	↓ Hepatic lipid content, ↓ Steatosis, ↓Inflammation, ↓ Fibrosis	[179]
PPAR agonist	Pioglitazone	NASH	↓Hepatic lipid content, ↓ ALT/AST	[184]
	Elafibranor	Abdominally obese insulin-resistant males	↓ ALT/AST, ↑ Insulin sensitivity	[188]
	Saroglitazar	NASH	↓ Hepatic lipid content	[219]
	Lanifibranor	NASH	↓ Hepatic lipid content, ↓Inflammation, ↓ Fibrosis	[189]
SGLT-2 inhibitor	Dapagliflozin	Type 2 diabetes	↓ Hepatic lipid content	[192]
SGLT-2 inhibitor	Empagliflozin	NAFLD	↓ Hepatic lipid content, ↓ ALT/AST	[191]
GLP-1 modulator	Liraglutide	NASH	↑ Insulin sensitivity, ↓ NAS score, ↓ ALT/AST	[199]
GLP-1 modulator	Exenatide	NASH	↓Hepatic lipid content, ↓ ALT/AST, ↓ Inflammation	[196]
DPP4 inhibitor	Sitagliptin	NASH	No effect on NAS score	[206]
KHK inhibitor	PF-06835919	NASH	↓ Hepatic lipid content	[209]
Probiotics		NAFLD	No effect on hepatic lipid content and inflammation	[220]
Fecal transplantation		NAFLD	No effect on hepatic lipid content and inflammation	[210]
FXR agonist	Obeticholic acid	NASH	↓ Steatosis, ↓ Inflammation, ↓ Fibrosis	[212]
	Cilofexor	NASH	↓ Hepatic lipid content, ↓ Steatosis, ↓ Primary BAs	[213]
	EDP-305	NASH	↓ Hepatic lipid content, ↓ ALT	[214]
TRβ agonist	Resmetirom	NASH	↓ Hepatic lipid content, ↓ ALT/AST	[215]
FGF19 analogue	Aldafermin	NASH	↓ Hepatic lipid content, ↓ ALT/AST	[217]

Back to article page

ISSN: 1743-7075

Contact us

General enquiries: journalsubmissions@springernature.com